Experimental Evidence for the Anti-Metastatic Action of Ginsenoside Rg3: A Systematic Review

Int J Mol Sci. 2022 Aug 13;23(16):9077. doi: 10.3390/ijms23169077.

Abstract

Cancer metastasis is the leading cause of death in cancer patients. Due to the limitations of conventional cancer treatment, such as chemotherapy, there is a need for novel therapeutics to prevent metastasis. Ginsenoside Rg3, a major active component of Panax ginseng C.A. Meyer, inhibits tumor growth and has the potential to prevent tumor metastasis. Herein, we systematically reviewed the anti-metastatic effects of Rg3 from experimental studies. We searched for articles in three research databases, MEDLINE (PubMed), EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) through March 2022. In total, 14 studies (eight animal and six in vitro) provide data on the anti-metastatic effects of Rg3 and the relevant mechanisms. The major anti-metastatic mechanisms of Rg3 involve cancer stemness, epithelial mesenchymal transition (EMT) behavior, and angiogenesis. Taken together, Rg3 would be one of the herbal resources in anti-metastatic drug developments through further well-designed investigations and clinical studies. Our review provides valuable reference data for Rg3-derived studies targeting tumor metastasis.

Keywords: cancer metastasis; ginsenoside Rg3; systematic review.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Epithelial-Mesenchymal Transition
  • Ginsenosides* / pharmacology
  • Ginsenosides* / therapeutic use
  • Lung Neoplasms* / pathology
  • Panax*

Substances

  • Ginsenosides
  • ginsenoside Rg3